Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncorena AB currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit, which indicates a concentrated prosecution focus for the company's active portfolio. Such a narrow distribution means that the company's immediate results are dependent on the evaluation of a single individual within a specific technical group at the USPTO. Practitioners should note that this concentration means the outcome of the portfolio is tied to the specific technical group and individual examiner assigned.
The busiest examiner for this portfolio is PRAGANI, RAJAN, who is responsible for 1 pending office action. This examiner handles the only pending action identified in the data, as the count of 1 pending action matches the number of distinct examiners and art units. For a practitioner, this means that understanding the specific examination style of PRAGANI, RAJAN is a critical factor in managing the company's current patent applications. The lack of diversity in examiners or art units for this 1 pending matter simplifies the administrative tracking but increases the impact of any single examiner's decision on the overall portfolio. The company's strategy in the Biotechnology & Pharmaceuticals sector must be highly targeted to address the requirements of this single point of interaction.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRAGANI, RAJAN | 1 | 52.4% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18880336 | ORELLANINE FORMULATION | PRAGANI, RAJAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18880336 | ORELLANINE FORMULATION | PRAGANI, RAJAN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18880336 | ORELLANINE FORMULATION | PRAGANI, RAJAN | 1614 | §101§103§112Other | Non-Final OA | — | Pending | Dec 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncorena AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rajan Pragani has the most, with 1 of Oncorena AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
